Quantcast

Latest Uric acid Stories

2011-04-06 09:15:00

SAN DIEGO, April 6, 2011 /PRNewswire/ -- Getting the word out about preventing and treating gouty arthritis has new urgency with the number of Americans suffering from this form of arthritis now topping the 8 million mark. If left untreated, gout can be disabling. Gout is also associated with other serious health conditions, making it a complex diagnosis and treatment challenge for physicians. In addition to the core patient demographic of men age 40 plus, post-menopausal women are at...

2011-02-28 06:30:00

TARRYTOWN, N.Y., Feb. 28, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that in a second Phase 3 study (PRE-SURGE 2) in gout patients initiating allopurinol therapy, ARCALYST (rilonacept) met the primary and all secondary study endpoints. The primary endpoint was the number of gout flares per patient over the 16-week treatment period. Patients who received ARCALYST at a weekly, self-administered, subcutaneous dose of either 160 milligrams (mg) or 80...

2011-01-18 15:27:56

The amount of uric acid in one's joints may increase the likelihood of severe osteoarthritis, the most common form of arthritis worldwide, according to researchers at Duke University Medical Center. Osteoarthritis is a debilitating joint degeneration for which no drug has been proven to slow or halt its progression. Physicians can only offer to treat the symptoms associated with osteoarthritis, and people with the condition are often subject to a reduced quality of life. "Finding a way to...

2011-01-06 15:00:00

SAN DIEGO, Jan. 6, 2011 /PRNewswire/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced positive, preliminary, top-line results from its Phase 2b study of RDEA594 in combination with the current standard of care for the treatment of gout, allopurinol. Allopurinol currently accounts for greater than 90% of the unit sales of chronic gout prescription medications; however, in controlled trials, only 30-40% of gout patients respond adequately to allopurinol as defined by the...

2010-12-09 12:35:00

BURLINGTON, Mass., Dec. 9, 2010 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that by 2019 the acute gout drug market will triple in size to $117 million and the chronic gout drug market will reach $1.83 billion. According to the new report entitled Acute and Chronic Gout - New Agents Target Refractory Patients and Tap Market Opportunity, both markets will be driven by new high-priced biologics....

2010-12-08 07:00:00

EXTON, Pa., Dec. 8, 2010 /PRNewswire/ -- BioTrends Research Group, Inc. finds that although Allopurinol remains the gold standard uric acid lowering (UAL) therapy for gout in the European Union (EU), Teijin Pharma/Ipsen/Menarini's Adenuric (currently available in France, Germany and the United Kingdom) has already achieved significant market penetration. The uptake of Adenuric is particularly robust in France, where its patient share is approximately one-half that of Allopurinol in...

2010-11-30 12:36:00

EAST BRUNSWICK, N.J., Nov. 30, 2010 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that it is commencing shipment of KRYSTEXXA(TM) (pegloticase) to specialty distributors and that KRYSTEXXA will be commercially available by prescription in the United States effective December 1, 2010. A PEGylated uric acid specific enzyme, KRYSTEXXA was granted approval by the Food and Drug Administration (FDA) on September 14, 2010 for the treatment of chronic gout in adult...

2010-11-29 06:26:00

SHENYANG, China, Nov. 29, 2010 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (Nasdaq: SSRX) ("3SBio" or "Company"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that is has acquired worldwide rights of pegsiticase for all indications from EnzymeRx for a total consideration of US$6.25 million. Pegsiticase (Uricase-PEG 20) is a pegylated recombinant uricase derived from Candida utilis,...

2010-11-23 07:00:00

EXTON, Pa., Nov. 23, 2010 /PRNewswire/ -- BioTrends Research Group, Inc. is pleased to announce the recent publication of a syndicated report, TreatmentTrends®: Gout. This biannual report provides a comprehensive market overview of current and future treatment trends in gout based on a primary research study fielded among 60 primary care physicians (PCPs) and 123 rheumatologists in the U.S. The report focuses on chronic and acute therapies, perceived strengths and...

2010-11-12 08:07:58

(Ivanhoe Newswire) "“ Consumption of fructose-rich beverages, such as sugar-sweetened sodas and orange juice is associated with an increased risk of gout among women. Gout is an incredibly ppainful type of arthritis. "The increasing disease burden of gout in the United States over the last few decades (e.g., an annual incidence of 16/100,000 in 1977 vs. 42/100,000 in 1996) coincided with a substantial increase in soft drink and fructose consumption," Hyon K. Choi, M.D., Dr.P.H., of the...


Word of the Day
bodacious
  • Remarkable; prodigious.
  • Audacious; gutsy.
  • Completely; extremely.
  • Audaciously; boldly.
  • Impressively great in size; enormous; extraordinary.
This word is probably from the dialectal 'boldacious,' a blend of 'bold' and 'audacious.'
Related